Document Type
Original Article
Abstract
Background: Cancer clinics all over the globe have begun using sentinel lymph node (SLN) biopsy (SLNB) for node-negative early breast cancer since its debut. A negative SLN indicates that 95% to 100% of the other LNs in that axilla are also negative. To evaluate patent blue dye in S/lN biopsy and its consequences to identify axillary level of lymph node involvement, we will analyze its function in post-neoadjuvant chemotherapy treatment of locally advanced breast carcinoma. Methods: This is a prospective cohort research carried out on 20 female patients with LABC who received neoadjuvant chemotherapy and will complete their management by modified radical mastectomy or conservative breast surgery with sentinel LN assessment for 6 months. Patients underwent identification, detection of level of SLN and assessment of SLN pathology by frozen section (FzS). Results: Notable differences were found between among positive, negative and suspicious. Notable differences were found between between ALND (axillary LN dissection) and SLNB (P value= 0.007). Notable differences were found between between ALND and SLNB (P value= 0.006). Notable differences were found between between stained and non-stained LNs (P value= 0.019). Conclusions: SLN detection rate was 85%, ALND revealed 5 cases (25 %) were positive and 2 cases (10%) were negative. SLNB revealed one case (5%) was positive and 12 cases (60%) were negative. SLN detection rate definitely rose with experience, suggesting the existence of a learning curve.
Keywords
sentinel lymph nodes, breast cancer, neoadjuvant chemotherapy
Subject Area
Onco-surgery
How to Cite This Article
Sheta, Ahmed Mohamed; Asar, Mohamed Mamdouh; and Abd-Elmonem, Ashraf Abd-Elhamid
(2023)
"Assessment of lymph nodes status post neoadjuvant chemotherapy using sentinel lymph nodes in locally advanced breast cancer,"
Al-Azhar International Medical Journal: Vol. 4:
Iss.
10, Article 40.
DOI: https://doi.org/10.58675/2682-339X.1979
